Why This Matters
Most Alzheimer's drug research has aimed at a single target: clearing the amyloid-beta or tau proteins that accumulate in the brains of people with the disease. That strategy has produced some clinically approved drugs but has also seen a long history of promising trial results that did not translate into meaningful benefit for patients.
